Figure 6.

Effects of CB₂R agonist treatment on T-lymphocyte infiltration into the LSC of LP-BM5-infected animals. After LP-BM5 infection, synthetic CB₂R ligands were injected (5 mg/kg, i.p.) twice/wk starting at 5 or 6 wk (HU308) p.i. At 12 wk p.i., LSCs were dissected and infiltrating leukocytes were banded on a 30–70% Percoll cushion, collected, and labeled with Abs specific for CD45, CD4, and CD8 for analysis by flow cytometry. (a) Representative contour plots show percentages of CD4⁺ and CD8⁺ T-lymphocytes within uninfected (UI), infected (IF), and infected (IF + indicated CB₂R ligand), agonist-treated LSC. (b) Frequency and number of CD4⁺ T-cells infiltrating into the LSC of animals belonging to the indicated treatment groups. (c) Frequency and number of CD8⁺ T-cells infiltrating into the LSC of animals belonging to the indicated treatment groups. Pooled data present absolute numbers (mean ± SE) of CD4⁺ and CD8⁺ T-cells from two independent experiments using 4–6 animals per group. ^∗p < 0.05; ^∗∗∗p < 0.001.